Copyright © 2021. Inderes Oyj. All rights reserved.

CellaVision

Analyst

Latest insider trading

Net impact profile

Third party research
26.10.
2022

Redeyes view on the Q3 report. The report was weak, in our opinion, even considering the challenges in the market and the typical seasonal fluctuation. Up to this point, the development in 2022 has been solid.

Third party research
20.7.
2022

Redeyes view on the Q2 report. With a powerful report and above our estimates, we adjust our forecasts for the rest of the current year. We increase our Base case to SEK 370 (340) and fair value range to SEK 230 – 520 (220 – 490) per share.

Third party research
10.5.
2022

Redeyes view on the Q1 report. With a report slightly above our estimates, we only make minor adjustments to our forecasts for the current year. We leave our Base case at SEK 340 unchanged.

Third party research
7.2.
2022

Redeyes view on the Q4 report. We make minor adjustments to our estimates for 2022, with a slightly lower growth assumption. We adjust our Base case to SEK 340 (330) per share with an unchanged fair value range.

Third party research
4.2.
2022

Redeyes's first comments on the Q4 report earlier this morning.

Third party research
22.10.
2021

Redeyes's first comments on the Q3 report earlier this morning.

Third party research
20.7.
2021

Redeye views the Q2 from Cellavision this morning as very much in line with our expectations and continued solid recovery story.

Third party research
28.4.
2021

Redeye’s first comments on CellaVision’s report for Q1’21. The report showed stronger sales than we expected at SEK 134m vs. our SEK 123m, a flat development compared to last year.

CellaVision